CD40LG and B-cell chronic lymphocytic leukemia: Based on these preclinical results, Wierda et al. have designed a phase I study to explore the clinical efficacy of a cancer vaccine consisting of autologous CLL cells genetically modified to express a human form of the CD40L molecule.